2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018

Susan Arnold 1 , Simon Platt 2 , Georgina Stewart 2 , Marc Kent 2 , Renee Barber 2 1 University of Georgia, Athens, GA, USA, 2 University of Georgia Veterinary Teaching Hospital, Athens, GA, USA Primary intraparenchymal brain tumors, including astrocytomas, glioblastomas, and oligodendrogliomas, collectively comprise approximately 35% of all primary brain tumors in dogs. The prognosis for dogs with any of these tumor types is generally guarded to poor. The median survival time regardless of treatment type is approximately 230 days. Due to numerous challenges associated with diagnosing, grading, treating, and reporting survival outcomes, there is currently no gold standard therapy for these tumors in dogs. Additionally, the similarities between canine and human primary intraparenchymal brain tumors lend translational opportunity to the development of novel treatment delivery systems for canine brain tumors. Glial tumors invade and migrate along white matter tracts and blood vessels, which is a characteristic that can be exploited. Catheters lined with nanofiber particles have been developed to structurally mimic these conduits.